NCT00163085已完成2 期
A Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Explore The Efficacy And Safety Of The NR2B NMDA Antagonist CP-101,606 In Patients With Idiopathic Parkinson's Disease
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 12
- 试验地点
- 2
- 主要终点
- Dyskinesia Rating Scale
研究概览
简要总结
To determine the effects of the NMDA antagonist, CP-101,606, in subjects with Parkinson's Disease
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 30 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •30- 80-year-old PD patients (UK Parkinson's Disease Brain Bank criteria) with a Hoehn & Yahr stage score of 2-5 in the "off" state.
排除标准
- •Subjects with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
结局指标
主要结局
Dyskinesia Rating Scale
次要结局
- Fingertapping
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With MDDDepressive Disorder, MajorNCT00163059Pfizer30
已完成
4 期
The Effect of Donepezil on Gait and Balance in Parkinson's DiseaseParkinson's DiseaseNCT01521117Oregon Health and Science University21
已完成
4 期
Stalevo in Early Wearing-Off PatientsIdiopathic Parkinson's DiseaseNCT00125567Orion Corporation, Orion Pharma223
已完成
2 期
A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's DiseaseParkinson's DiseaseNCT01603069AstraZeneca51
已完成
3 期
Efficacy, Safety, Tolerability of Pramipexol ER Versus Pramipexol IR Versus Placebo in Early PD PatientsEarly Parkinson Disease (Early PD)NCT00479401Boehringer Ingelheim539